Curis Inc Virtual KOL Event - Reviewing CA-4948 Clinical Data in NHL & AML/MDS Transcript
Good morning everyone, and welcome to our Virtual Key Opinion Leader call to discuss clinical data on our first-in-class IRAK4 inhibitor, CA-4948. 12 months ago, we outlined our goals for 2020 to provide data updates from both of our ongoing clinical trials of CA-4948. Today, we're excited to provide these updates.
For the NHL study, in a presentation yesterday at ASH, we formally identified our recommended Phase II dose, which has demonstrated tumor reduction in 6 of 7 patients and robust tolerability up to 2 years. All of this in single-agent therapy in a heavily pretreated patient population. These are patients who enrolled in our study after feeling on average 4 prior lines of treatment with other therapies.
In addition, we are especially excited about the identification of 2 new biomarkers, which we expect will help us with patient selection and enrichment as we advance into the combination study of CA-4948 with ibrutinib.
For the AML and MDS study, we are highly encouraged by the data released an hour ago.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |